Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06421376
Other study ID # NCC4475
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date May 1, 2024
Est. completion date December 31, 2027

Study information

Verified date May 2024
Source Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Contact Xin Wang, M.D.
Phone +861013311583220
Email beryl_wx2000@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Although unprecedented advances have been made in the field of esophageal cancer in recent decades, the prognosis for patients with locally advanced esophageal squamous cell carcinoma (ESCC) remains extremely poor, accounting for 30-40% of overall survival at 5 year. In recent years, multimodal treatments have proven to be an appropriate therapeutic approach for locally advanced ESCC. Recently, immunotherapy developed rapidly. The purpose of this study was to observe the efficacy and safety of cardonilizumab combined with chemoradiotherapy in the treatment of locally advanced ESCC.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date December 31, 2027
Est. primary completion date December 31, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - 18-80 years old; - Eligible patients were histologically confirmed esophageal squamous cell carcinoma; - Eligible patients were proven locally advanced ESCC (cT1-2N1-3M0-1, cT3/T4N0-3M0-1, M1 was limited to supraclavicular lymph node metastasis)diagnosed by computed tomography [CT] and/or endoscopic ultrasonography [EUS] according to the American Joint Committee on Cancer (AJCC) 8th edition staging system; - ECOG PS score: 0~1; - Main organs and bone marrow function are normal: routine blood tests: hemoglobin (Hb) =100g/L ; absolute neutrophil count (NEUT)=1.5×109/L; platelets (PLT) =100×109/L; white blood cell (WBC)=3.5×109/L,biochemical examination: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =1.5×UNL; serum total bilirubin (TBIL) =1.5×UNL; serum creatinine ( Cr) 1.0×1.5UNL, and BUN=1.0×UNL; Exclusion Criteria: - Those combined with other primary malignant tumors other than esophageal cancer (except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix); - patients who had previously received other treatments - At the time of diagnosis, there were distant and hematogenous metastases beyond the supraclavicular lymph node region, including retroperitoneal multiple lymph node metastasis, bone metastasis, brain metastasis, lung metastasis, liver metastasis, malignant pleural effusion and ascites - Those who already have esophageal perforation or are at high risk of esophageal perforation - Patients whose tumors invade close to large blood vessels and are at risk of bleeding in the - there are active infections, such as active tuberculosis and hepatitis - There are contraindications to immunotherapy. - Pregnant or lactating women and women of childbearing age do not take reliable contraceptive measures - Combined with serious cardiovascular diseases, such as uncontrolled heart failure, coronary heart disease, cardiomyopathy, uncontrolled arrhythmia, uncontrolled hypertension, or a history of myocardial infarction within the past 6 months; and those combined with other uncontrolled acute and chronic diseases such as hypertension and diabetes. - Violation of inclusion and exclusion criteria, or other reasons that the researcher believes cannot continue the study of drug treatment.

Study Design


Intervention

Drug:
Cardonilizumab
Two cycles of Inductive therapy: nab-paclitaxel 250mg/ m2+cisplatin 75mg/ m2+Cardonilizumab 10mg/kg,ivgtt,3 weeks per cycle for 2 cycles
Radiation:
Chemoradiotherapy ±immunotherapy
Chemoradiotherapy ± immunotherapy: PTV: 50-50.4Gy/1.8-2Gy/25-28fractions ?nab-paclitaxel 100mg+cisplatin 25mg/ m2, d1, every 7 days for 3-5 weeks ?Cardonilizumab 10mg/kg,ivgtt,3 weeks per cycle for 2 cycles
Procedure:
Radical surgery
Surgery was evaluated after concurrent chemoradiotherapy according to patients willing and the surgeons' assessment. If patients were accessed with unresectable disease after radiotherapy or refused to receive surgery, Cardonilizumab would be administered for 2 years or until disease progression.

Locations

Country Name City State
China Anyang Cancer Hospital Anyang Henan
China Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC) Beijing
China The First Affiliated Hospital of Xinxiang Medical University Xinxiang Henan

Sponsors (1)

Lead Sponsor Collaborator
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Event-free survival Time from treatment initiation to locoregional or distant recurrence, or death from any cause. 1-year
Secondary Overall survival The 1-year OS rate was defined as the proportion of patients who still alive within one year from treatment initiation. 1-year
Secondary Adverse events In terms of adverse events of radiation, chemotherapy and immunotherapy 1-year
Secondary Locoregional recurrence free survival The 1-year rate was defined as the proportion of patients who did not have any locoregional recurrence from treatment initiation. 1-year
Secondary Distant metastasis free survival The 1-year rate was defined as the proportion of patients who did not have any distant metastasis from treatment initiation. 1-year
See also
  Status Clinical Trial Phase
Recruiting NCT05583916 - Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery N/A
Completed NCT04448041 - CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
Completed NCT03213314 - HepaT1ca: Quantifying Liver Health in Surgical Candidates for Liver Malignancies N/A
Enrolling by invitation NCT05534490 - Surgery and Functionality in Older Adults N/A
Recruiting NCT04792983 - Cognition and the Immunology of Postoperative Outcomes
Terminated NCT04612491 - Pre-operative Consultation on Patient Anxiety and First-time Mohs Micrographic Surgery
Recruiting NCT06397287 - PROM Project Urology
Recruiting NCT04444544 - Quality of Life and High-Risk Abdominal Cancer Surgery
Completed NCT04204785 - Noise in the OR at Induction: Patient and Anesthesiologists Perceptions N/A
Completed NCT03432429 - Real Time Tissue Characterisation Using Mass Spectrometry REI-EXCISE iKnife Study
Completed NCT04176822 - Designing Animated Movie for Preoperative Period N/A
Recruiting NCT05370404 - Prescribing vs. Recommending Over-The-Counter (PROTECT) Analgesics for Patients With Postoperative Pain: N/A
Not yet recruiting NCT05467319 - Ferric Derisomaltose/Iron Isomaltoside and Outcomes in the Recovery of Gynecologic Oncology ERAS Phase 3
Recruiting NCT04602429 - Children's Acute Surgical Abdomen Programme
Completed NCT03124901 - Accuracy of Noninvasive Pulse Oximeter Measurement of Hemoglobin for Rainbow DCI Sensor N/A
Completed NCT04595695 - The Effect of Clear Masks in Improving Patient Relationships N/A
Recruiting NCT06103136 - Maestro 1.0 Post-Market Registry
Completed NCT05346588 - THRIVE Feasibility Trial Phase 3
Completed NCT04059328 - Novel Surgical Checklists for Gynecologic Laparoscopy in Haiti
Recruiting NCT03697278 - Monitoring Postoperative Patient-controlled Analgesia (PCA) N/A